Shaker is one of six receiving an individual award, which recognizes people, organizations and products bringing AI to life and applying it to solve real problems
The collaboration will utilize Avatar-Rx, LifeMine’s proprietary genomically-enabled drug discovery platform to access evolutionarily derived lead small molecules
The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's innovative business model to accelerate drug development and patient access to novel medicines at affordable prices
Arum's research focuses on the discovery of new chemical entities that will act as effective therapies for drug-resistant cancers
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
It is only the second generic application approved by the USFDA
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers
Subscribe To Our Newsletter & Stay Updated
